PCI Synthesis Announces 8th Successful FDA Inspection
Additionally, PCI received its sixth product pre-approval; with that pre-approval, PCI's partner expects to launch a new drug in Q1/Q2 2012. Over the past year, PCI launched five new proprietary APIs in the laboratory for the generic and OTC markets with exclusive supply agreements -- exceeding its goal of four per year.
PCI, which provides small and mid-sized companies with access to expertise for the development and manufacturing of complex small molecules to be used as APIs, is currently involved in the development of four late stage products recently included in MM&M's "Pipeline 2011" list of top launch prospects.
"The latest successful FDA audit validates the ongoing investments we have made in our people, our cGMP systems, our research, and to our continual process improvement. We have a smart team that understands the complex dynamics of small molecules, from making molecules, optimizing molecules, performing process improvements, and scaling up," said Edward S. Price, President of PCI Synthesis. "Our focus and commitment to R&D is paying off, with our sixth product pre-approval, which assures the company of a steady stream of products in the years to come."
About PCI Synthesis
PCI Synthesis is a 12-year-old custom chemical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products. A contract manufacturing organization (CMO), PCI provides emerging and mid-sized pharmaceutical companies access to the expertise needed to develop and manufacture complex small molecules and APIs used in generic pharmaceuticals. To learn more about PCI Synthesis, its proprietary NCE development activities and process R&D capabilities, please visit www.pcisynthesis.com